Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Single dose of fast-acting psychedelic nasal spray shows promise for stubborn depression (opens in a new tab)

medicalxpress.com · 2026-10-28

Short answerEvidenceSource

Short answer

Mixed

Mixed.

2 claims go further than the study. One other point was not covered by the paper.

  • 3 supported
  • 2 overstated
  • 1 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Two of six claims overstate the study. Three of six check out. One claim the study doesn't address.

  • 3 supported
  • 2 overstated
  • 1 not covered
Open claim evidence
3
Source paper

Source layer

The 2 papers the story cites

Source study separated from background citations.

The research anchor for the report.

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

6 claims in this story

Showing all 6 claimsChoose a verdict to focus the list.

Claim 1 of 6OverstatedAfter a single medium or high dose, depression symptoms began to ease within a day and the improvement held for up to eight weeks.View evidenceHide evidence

As statedup to eight weeks

Why this verdict

The profile supports larger MADRS reductions for 8 mg and 12 mg versus 0.3 mg through day 29 and at time points from day 2 to day 57, broadly consistent with improvement lasting up to about 8 weeks. But the headline-level claim that symptoms 'began to ease within a day' is not supported by the supplied abstract profile, which specifies significance from day 2 onward rather than within 24 hours. As a headline claim, it outruns the profile evidence and appears stronger/more precise than the supported body-level day-29 and day-57 findings.

1

Study evidence

12 mg intranasal mebufotenin benzoate produced greater reduction in depressive symptoms than the 0.3-mg comparator at day 29.Mean difference in MADRS change -5.3 (95% CI -8.9 to -1.8); P = .003 (12 mg vs 0.3 mg, baseline to day 29).

“Phase 2b, randomized, double-blind trial with an 8-week blinded follow-up”
Claim 2 of 6OverstatedAcross the three dose groups, 78% to 85% of participants were ready for discharge within two hours because the spray's effects wore off quickly.View evidenceHide evidence

As stated78% to 85% within two hours

Why this verdict

The profile supports that most active-dose participants were ready for discharge within 2 hours: 85% for 8 mg and 78% for 12 mg. However, the profile does not report this range across all three dose groups; readiness data for the 0.3-mg comparator are not provided. The story also adds a causal explanation—'because the spray's effects wore off quickly'—that is not established by the abstract-level profile, which reports discharge readiness rather than directly proving why readiness occurred.

1

Study evidence

Most participants receiving intranasal mebufotenin were deemed ready for discharge within ~2 hours post dose.85% (8 mg); 78% (12 mg)

“Discharge readiness was assessed starting 90 minutes after dosing.”
2

Study evidence

Incidence of any treatment-emergent adverse events was reported in 76% of participants in the 8-mg group, 85% in the 12-mg group, and 73% in the 0.3-mg comparator group.76% (8 mg); 85% (12 mg); 73% (0.3 mg)

“Treatment-emergent adverse events were reported in 76%, 85%, and 73% of participants in the 8-mg, 12-mg, and 0.3-mg dose groups, respectively; most events (99.7%) were mild or moderate.”
Claim 3 of 6Not coveredThe article says future studies with longer observation periods are needed to determine how long benefits last and whether repeat dosing is needed.View evidenceHide evidence

Why this verdict

The supplied profile supports that the trial used a single dose and followed participants for 8 weeks, which makes longer-term durability and repeat dosing open questions. However, the abstract-level profile does not explicitly report a future-studies statement about longer observation periods or repeat dosing. This is plausible but not directly verifiable from the supplied abstract-depth evidence.

1

Study evidence

12 mg intranasal mebufotenin benzoate produced greater reduction in depressive symptoms than the 0.3-mg comparator at day 29.Mean difference in MADRS change -5.3 (95% CI -8.9 to -1.8); P = .003 (12 mg vs 0.3 mg, baseline to day 29).

“Phase 2b, randomized, double-blind trial with an 8-week blinded follow-up”
Claim 4 of 6SupportedA recent study published in JAMA investigated whether intranasal mebufotenin benzoate could be a fast-acting psychedelic option for treatment-resistant depression.View evidenceHide evidence

Why this verdict

The abstract-level profile supports that this was a recent JAMA phase 2b randomized, double-blind trial evaluating single-dose intranasal mebufotenin benzoate for adults with treatment-resistant depression, including efficacy over 8 weeks. The story’s framing as investigating a possible fast-acting psychedelic option is appropriately hedged.

1

Study evidence

12 mg intranasal mebufotenin benzoate produced greater reduction in depressive symptoms than the 0.3-mg comparator at day 29.Mean difference in MADRS change -5.3 (95% CI -8.9 to -1.8); P = .003 (12 mg vs 0.3 mg, baseline to day 29).

“Phase 2b, randomized, double-blind trial with an 8-week blinded follow-up”
Claim 5 of 6SupportedThe researchers enrolled adults ages 18 to 75 with treatment-resistant depression across 38 clinical sites in the U.S., Australia and Europe, and randomly assigned them to 12 mg, 8 mg or 0.3 mg doses in a blinded study.View evidenceHide evidence

As stated193 adults; 38 sites; three dose groups

Why this verdict

The profile reports adults aged 18–75 with treatment-resistant major depressive disorder, 193 total participants, 38 sites across Australia, Europe, and the US, randomized in a double-blind trial to 8 mg, 12 mg, or 0.3 mg intranasal mebufotenin benzoate. The story’s methodological description matches the abstract-level evidence.

1

Study evidence

12 mg intranasal mebufotenin benzoate produced greater reduction in depressive symptoms than the 0.3-mg comparator at day 29.Mean difference in MADRS change -5.3 (95% CI -8.9 to -1.8); P = .003 (12 mg vs 0.3 mg, baseline to day 29).

“Phase 2b, randomized, double-blind trial with an 8-week blinded follow-up”
Claim 6 of 6SupportedFour weeks later, the 12 mg dose lowered clinician-rated depression scores by about five points more than the low-dose control on a 60-point scale, and roughly one-third of participants receiving either higher dose had symptom scores fall by at least half.View evidenceHide evidence

As statedabout five points; roughly one-third

Why this verdict

The profile reports the day-29 primary comparison for 12 mg vs 0.3 mg as a MADRS mean difference of -5.3 points, matching the story’s 'about five points' claim. It also reports day-29 response rates of 35% for 8 mg and 34% for 12 mg, consistent with 'roughly one-third' having symptom scores fall by at least half. The abstract profile supports the core magnitude and direction of this claim.

1

Study evidence

12 mg intranasal mebufotenin benzoate produced greater reduction in depressive symptoms than the 0.3-mg comparator at day 29.Mean difference in MADRS change -5.3 (95% CI -8.9 to -1.8); P = .003 (12 mg vs 0.3 mg, baseline to day 29).

“Phase 2b, randomized, double-blind trial with an 8-week blinded follow-up”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Day-29 remission rates also favored active doses: 26% for 8 mg and 18% for 12 mg versus 8% for 0.3 mg.

    The profile includes remission as a clinically relevant outcome, but the story presentation only mentions response rates and does not report remission.

    From Phase 2b randomized, double-blind, parallel-group intranasal dose-comparison trial

  • Safety/tolerability finding: treatment-emergent adverse events were common across groups but 99.7% were mild or moderate.

    Safety was one of the paper’s primary contribution areas. The story mentions brief psychedelic effects and discharge readiness but does not reflect the reported adverse-event incidence or the mild/moderate severity finding.

    From Phase 2b randomized, double-blind trial (single-dose intranasal administration)

  • Important limitation for discharge-readiness interpretation: the abstract does not report readiness data for the 0.3-mg comparator group, formal comparative statistics, detailed readiness criteria, or time-to-event distributions.

    This caveat is material because the story generalizes discharge readiness across three dose groups and implies a mechanism. The story presentation does not acknowledge that the abstract-level profile lacks comparator readiness data and detailed criteria.

    From Randomized, double-blind trial procedural monitoring

  • Intervention context included psychological support and antidepressant washout as needed before dosing.

    The story frames the intervention mainly as the intranasal drug dose. The profile indicates participants also received psychological support and underwent antidepressant washout as needed, which is relevant context for interpreting the treatment protocol.

    From Phase 2b randomized, double-blind, parallel-group intranasal dose-comparison trial

5 things the story did carry across
  • Phase 2b randomized, double-blind, multisite single-dose trial in adults aged 18–75 with treatment-resistant major depressive disorder, comparing 8 mg and 12 mg intranasal mebufotenin benzoate with a 0.3-mg low-dose comparator.
  • Primary efficacy finding: 12 mg produced greater MADRS reduction than 0.3 mg at day 29; 8 mg also showed greater reductions, with active-dose effects reported through day 57.
  • Day-29 clinical response rates favored active doses: 35% for 8 mg and 34% for 12 mg versus 12% for 0.3 mg.
  • Discharge-readiness finding: discharge readiness was assessed starting 90 minutes after dosing, and most active-dose participants were ready within 2 hours: 85% for 8 mg and 78% for 12 mg.
  • Duration limitation: the trial was a single-dose study with blinded follow-up for 8 weeks, so longer-term durability and repeat-dosing needs are not established by the abstract-level profile.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

3

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoEvaluate efficacy of a single intranasal dose of mebufotenin benzoate (8 mg or 12 mg) vs a low-dose comparator (0.3 mg) for reducing depressive symptoms in adults with treatment-resistant depression over an 8-week blinded follow-up.Phase 2b randomized, double-blind, parallel-group intranasal dose-comparison trialExpand

In plain English

Phase 2b randomized, double-blind, multi-site trial evaluating single intranasal doses of mebufotenin benzoate (8 mg and 12 mg) versus a low-dose comparator (0.3 mg) in adults with treatment-resistant major depressive disorder. The prespecified primary outcome compared change in MADRS total score from baseline to day 29 for 12 mg vs 0.3 mg. Both active doses produced larger mean MADRS reductions versus the 0.3-mg comparator through day 29 and at multiple time points up to day 57; adverse events were common but mostly mild/moderate, and most participants were ready for discharge within 2 hours.

Key findings

  • 12 mg intranasal mebufotenin benzoate produced greater reduction in depressive symptoms than the 0.3-mg comparator at day 29.Mean difference in MADRS change -5.3 (95% CI -8.9 to -1.8); P = .003 (12 mg vs 0.3 mg, baseline to day 29).
  • 8 mg intranasal mebufotenin benzoate also produced greater reduction in depressive symptoms than the 0.3-mg comparator at day 29.Mean difference in MADRS change -6.2 (95% CI -10.2 to -2.1); P = .003 (8 mg vs 0.3 mg, baseline to day 29).
“Phase 2b, randomized, double-blind trial with an 8-week blinded follow-up”
2human in vivoEvaluate safety/tolerability (treatment-emergent adverse events) of single-dose intranasal mebufotenin benzoate at 8 mg and 12 mg vs 0.3 mg in the same trial population.Phase 2b randomized, double-blind trial (single-dose intranasal administration)Expand

In plain English

In this randomized, double-blind phase 2b trial of single-dose intranasal mebufotenin benzoate in adults with treatment-resistant depression, adverse events were common across dose groups but were reported as mostly mild or moderate; reported incidence of any treatment-emergent adverse events was 76% (8 mg), 85% (12 mg), and 73% (0.3 mg). Most participants were deemed ready for discharge within 2 hours (85% for 8 mg; 78% for 12 mg).

Key findings

  • Incidence of any treatment-emergent adverse events was reported in 76% of participants in the 8-mg group, 85% in the 12-mg group, and 73% in the 0.3-mg comparator group.76% (8 mg); 85% (12 mg); 73% (0.3 mg)
  • The vast majority of reported adverse events were described as mild or moderate.99.7% of reported events classified as mild or moderate
“Treatment-emergent adverse events were reported in 76%, 85%, and 73% of participants in the 8-mg, 12-mg, and 0.3-mg dose groups, respectively; most events (99.7%) were mild or moderate.”
What this piece can’t prove
  • The abstract does not provide subgroup safety analyses or longer-term safety outcomes beyond the 8-week blinded follow-up mention.

3 further details could not be confirmed from the summary.

3human in vivoEvaluate feasibility/logistics via time to discharge readiness after dosing (starting 90 minutes post dose), comparing dose groups.Randomized, double-blind trial procedural monitoringExpand

In plain English

Within this randomized, double-blind phase 2b trial, discharge readiness was assessed starting 90 minutes after a single intranasal dose of mebufotenin benzoate. Most participants receiving active doses were reported as ready for discharge within ~2 hours (85% for 8 mg; 78% for 12 mg).

Key findings

  • Most participants receiving intranasal mebufotenin were deemed ready for discharge within ~2 hours post dose.85% (8 mg); 78% (12 mg)
“Discharge readiness was assessed starting 90 minutes after dosing.”
What this piece can’t prove
  • Abstract reports proportions within a ~2-hour window but does not provide formal statistical comparisons between dose groups for this endpoint.

3 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 39 candidate papers

And 33 more candidates considered.